Olaparib alone reduced mRNA expression levels of MMP2 and MMP9 in oral carcinoma cell lines [23] and, combined with bevacizumab, was found to reduce the serum levels of MMP9 in advanced colorectal cancer [24]. This evidence concerns the gene MMP2 and lip and oral cavity carcinoma.